The Future of Restless Legs Syndrome Treatments Market: What’s on the Horizon
The Future of Restless Legs Syndrome Treatments Market: What’s on the Horizon
Blog Article
Market Overview
Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an urge to move the legs usually due to uncomfortable sensations. it commonly occurs during periods of rest like when sitting or lying down.The primary treatments for RLS include dopaminergic medications like pramipexole, ropinirole, and gabapentin.
These drugs work by increasing dopamine levels in the brain and reducing nerve sensitivity which helps relieve Restless Legs Syndrome Treatment Market symptoms. They are prescribed based on the severity and frequency of symptoms. Non-drug treatments involve lifestyle changes, physical therapy, and deep brain stimulation.
The restless legs syndrome treatment market is estimated to be valued at USD 2.5 Bn in 2024 and is expected to reach USD 2.64 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.
Key Takeaways
Key players: The major players operating in the restless legs syndrome treatment market are GlaxoSmithKline plc, Ligand Pharmaceuticals, Jazz Pharmaceuticals, Sunovion Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.
Growing demand: The market is witnessing increased demand for improved therapeutics owing to rising awareness regarding RLS and available treatment options. As per studies, around 10% of adults worldwide experience RLS at least once a month.
Technological advancement: Companies are increasingly investing in developing new drugs with novel mechanism of actions and improved efficacy and safety profiles. Some innovative drugs in the pipeline target opioid and adenosine receptors to relieve symptoms.
Market Trends
Increased prescription of off-label drugs: Due to lack of approved treatments for mild to moderate RLS, off-label prescription of antidepressants, anti-epileptics, and antipsychotics is on the rise. Drugs like trazodone, gabapentin, and quetiapine are commonly used.
Focus on combination therapies: Given the complexity of RLS pathology, combined medication regimens using dopaminergic agents along with alpha-2 delta ligands are gaining traction. Their synergistic action provides enhanced relief.
Market Opportunities
Pediatric RLS treatment: Current therapeutics are only approved for adults while RLS also occurs in 10-15% children. Developing pediatric formulations and studying efficacy in younger population presents an opportunity.
Targeting root cause: Majority of RLS cases have unknown cause. Opportunities exist in developing etiology-based treatments targeting iron deficiency, genetic dysfunction or abnormal neural activity.
Impact of COVID-19 on Restless Legs Syndrome Treatment Market:
The COVID-19 pandemic has significantly impacted the restless legs syndrome treatment market. During the initial phase of lockdowns imposed globally, numerous non-essential medical services were postponed which included restless legs syndrome treatments. This led to reduced demand for restless legs syndrome drugs in 2020. However, with relaxations in lockdown restrictions in 2021, the market is gradually recovering.
The pandemic disrupted the supply chain of key pharmaceutical ingredients. This led to shortages and delays in manufacturing of some restless legs syndrome drugs. Telemedicine emerged as a boon during the pandemic to continue providing guidance to patients regarding management of symptoms. Various mobile apps and online doctor consultation platforms were utilized for restless legs syndrome treatment guidance.
With work from home culture and stress/anxiety levels rising among general public due to the pandemic, cases of restless legs syndrome also increased during 2020-21. This has created more awareness about the condition and treatment options. Going forward, market players are expected to focus on ensuring stable supply chain to meet the growing demand and expanding telemedicine/digital health solutions for restless legs syndrome management.
Geographical Regions with Highest Value Concentration in Restless Legs Syndrome Treatment Market:
The North American region accounts for the largest share of the global restless legs syndrome treatment market in terms of value. This is majorly due to high diagnosed patient base and relatively greater awareness among population and healthcare providers regarding the condition and availability of treatment options. The United States constitutes a major chunk of the North American market. Growing geriatric population prone to restless legs syndrome and favorable reimbursement policies further support market growth in the region.
Fastest Growing Region in Restless Legs Syndrome Treatment Market:
The Asia Pacific region is expected to witness the fastest growth in the restless legs syndrome treatment market over the forecast period. This is attributed to factors like rising living standards, increasing healthcare spending, growing geriatric population, and expanding healthcare infrastructure in various Asia Pacific countries like China and India. Greater adoption of digital health solutions for restless legs syndrome management will further aid market expansion. Rising incidence of lifestyle diseases also contributes to the growth. Initiation of awareness programs regarding restless legs syndrome is another factor supporting market growth.
Get more insights on: Restless Legs Syndrome Treatment Market
Explore more related articles - Understanding Colorectal Cancer Screening in the United States
About Author: Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)